sRAGE plays a role as a protective factor in the development of PCOS by inhibiting inflammation

Abstract

This study determined the effect of exogenous soluble receptor for advanced glycation end products (sRAGE) on the pro-inflammatory activities that occur during polycystic ovary syndrome (PCOS) in human follicular cells and explored a potential mechanism for preventing the development of inflammation. Follicular fluid was allocated into one of three treatment groups (0, 0.6, and 1.2 μg mL⁻¹ of sRAGE). Collectively, these results indicate that exogenous sRAGE supplementation alleviates inflammation in ovarian follicular granulosa cells by regulating p-ERK and AP-1 signaling.

摘要

本研究测定了外源性晚期糖基化终产物可溶性受体（sRAGE）对多囊卵巢综合征(PCOS)患者卵泡细胞促炎活性的影响, 并探讨其可能的抗炎机制。卵泡液被分为三组（0, 0.6, and 1.2 μg mL^-1 of sRAGE）。总之, 这些结果表明, 外源性sRAGE通过调节p-ERK和AP-1信号通路, 减轻了卵泡颗粒细胞的炎症反应。

Keywords:

• sRAGE
• inflammation
• reproduction
• PCOS
• therapy

Disclosure statement

The authors declare that they have no conflict of interests.

Additional information

Funding

This work was supported by grant [81571409] from the National Natural Science Foundation: The mechanism of sRAGE in the regulation of VEGF production in granulosa cells of PCOS; and grant [17020320701] from the Special fund for clinical research of the Chinese Medical Association: Protective effects and molecular mechanism of sRAGE on inhibiting inflammation and improving insulin resistance in PCOS; the Special fund for clinical research of Chinese Medical Association.